XM does not provide services to residents of the United States of America.
E
E

EXACT

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

U.S. Akamai Technologies, Bill Holdings, Veeva Systems

U.S. RESEARCH ROUNDUP- Akamai Technologies, Bill Holdings, Veeva Systems Nov 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Akamai Technologies, Bill Holdings and Veeva Systems, on Monday. HIGHLIGHTS * Akamai Technologies Inc AKAM.O : HSBC raises target price to $121 from $107 * Bill Holdings Inc BILL.N : Jefferies raises target price to $92 from $65 * Charles River Laboratories International CRL.N : TD Cowen rai
A
E
E
A

Exact Sciences slumps after lowering full-year revenue forecast

BUZZ-Exact Sciences slumps after lowering full-year revenue forecast ** Cancer test maker Exact Sciences' EXAS.O shares down 24.9% at $53.72 ** After market close on Tuesday, company lowered its 2024 total revenue and screening revenue forecast ** Company now sees its revenue forecast in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln ** "The single biggest reason for why revenue would be down sequentially from Q3 to Q4 is the hurricanes." CFO Aaron Bloomer said i
E

U.S. Apollo, Booking Holdings, Portillos

U.S. RESEARCH ROUNDUP-Apollo, Booking Holdings, Portillos Nov 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apollo, Booking Holdings and Portillos, on Wednesday. HIGHLIGHTS * Apollo APO.N : JP Morgan raises target price to $161 from $143 * Aris Water Solutions Inc ARIS.N : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Truist Securities raises target to $4,700 from $4,100 * Choice Hotel
A
E
M
C
F
X
B
C
C
E
G
L

Exact Sciences Corp reports results for the quarter ended in September 30 - Earnings Summary

Exact Sciences Corp reports results for the quarter ended in September 30 - Earnings Summary Exact Sciences Corp EXAS.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of twenty three analysts for the quarter was for a loss of 21 cents per share.
E

Exact Sciences falls after company cuts 2024 revenue forecast

BUZZ-Exact Sciences falls after company cuts 2024 revenue forecast ** Shares of cancer test maker Exact Sciences EXAS.O fall 27.3% to $52 after the bell ** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln ** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG ** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 b
E

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.